About
Profile
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
BIIB
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth
- Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook
- Biogen reports Q2 results
- Biogen rises as Alzheimer’s therapy drives Q2 beat
- Biogen Q2 2025 Earnings Preview
- Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs
- KalVista, Biogen, Ionis get EU positive opinions for key drugs
- Biogen to invest additional $2B in North Carolina’s Research Triangle Park
- Biogen sees negative Q2 impact from IPR&D, milestone expenses
- Biogen starts phase 3 trial of felzartamab for kidney disease
- Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy
- Biogen’s salanersen shows promise in SMA, heads toward registrational trials
- Lilly to appeal as U.K. declines to endorse use of new Alzheimer’s drugs
- Biogen and City Therapeutics partner to develop RNAi therapies
- Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen
- FDA greenlights first blood test to diagnose Alzheimer's disease
- Insider trades: Microsoft, JPMorgan, Boeing among notable names this week
- Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025
- Earnings Snapshot: Biogen FY profit outlook misses estimates even as Q1 beats
- Biogen Non-GAAP EPS of $3.02, revenue of $2.43B
Earnings History
| Date | EPS / Forecast | Revenue / Forecast | |
|---|---|---|---|
| February 3, 2022 | 3.39 / 3.35 | 2.73B / 2.62B |
Beat! |
| October 20, 2021 | 4.77 / 4.09 | 2.78B / 2.67B |
Beat! |
| July 22, 2021 | 5.68 / 4.55 | 2.78B / 2.61B |
Beat! |
| April 22, 2021 | 5.34 / 4.98 | 2.69B / 2.65B |
Beat! |
| February 3, 2021 | 4.58 / 4.79 | 2.85B / 2.8B |
Beat! |
| October 21, 2020 | 8.84 / 8.09 | 3.38B / 3.33B |
Beat! |
| July 22, 2020 | 10.26 / 8.02 | 3.68B / 3.43B |
Beat! |
| April 22, 2020 | 9.14 / 7.72 | 3.53B / 3.42B |
Beat! |
| January 30, 2020 | 8.34 / 8.03 | 3.67B / 3.54B |
Beat! |
| October 22, 2019 | 9.17 / 8.3 | 3.6B / 3.54B |
Beat! |
| July 23, 2019 | 9.15 / 7.53 | 3.62B / 3.47B |
Beat! |
| April 24, 2019 | 6.98 / 6.97 | 3.49B / 3.4B |
Beat! |
| January 29, 2019 | 6.99 / 6.73 | 3.53B / 3.39B |
Beat! |
| October 23, 2018 | 7.4 / 6.78 | 3.44B / 3.33B |
Beat! |
| July 24, 2018 | 5.8 / 5.21 | 3.36B / 3.25B |
Beat! |
| April 24, 2018 | 6.05 / 5.93 | 3.13B / 3.15B | |
| January 25, 2018 | 5.26 / 5.45 | 3.31B / 3,080M |
Beat! |
| October 24, 2017 | 6.31 / 5.73 | 3.08B / 3,044M |
Beat! |
| July 25, 2017 | 5.04 / 5.62 | 3.08B / 2.81B |
Beat! |
| April 25, 2017 | 5.2 / 4.6 | 2.81B / - |
Beat! |
| January 26, 2017 | 5.04 / 5.01 | 2.87B / 2.94B |